Tag Archives: Biotechnology

Business Economy Finances

Creating innovations – for 150 years

Analytica 2018 – Greiner Bio-One presents innovations for successful work in the laboratory

Creating innovations - for 150 years

The single-layer version of CELLdisc simplifies the monitoring and analysis of mass cell cultures. (Source: Greiner Bio-One)

Frickenhausen, April 3rd, 2018 – Greiner Bio-One GmbH, technology partner for the diagnostic and pharmaceutical industry, is unveiling numerous product innovations at Analytica 2018, the leading international trade fair for laboratory technology, analysis and biotechnology, in Munich. This year’s exhibits include Sapphire pipettes for liquid handling, boasting impressive user-friendliness and precision, the 5 ml centrifuge tubes, which are an optimum addition to the portfolio of reaction vessels and tubes, and the new single-layer cell culture vessel from the proven CELLdisc range.

In the field of microscopy, Greiner Bio-One is also showcasing a wide variety of carefully designed CELLview cell culture products with a glass bottom in the form of slides, dishes and plates. The complete portfolio for 3D cell culture is also being exhibited at Analytica 2018. Cell culture vessels with a cell-repellent surface enable the cultivation of cells into three-dimensional structures and represent a perfect platform for magnetic 3D cell culture.

Visitors will also be able to find out more about all the high-tech products for biobanking. With its Cryo.s biobanking tubes, 8-channel decapper and rack scanner, Greiner Bio-One offers perfectly coordinated solutions for sample storage with high throughput and in automated storage systems.

Successful development
The BioScience division of Greiner Bio-One, headquartered in Frickenhausen in the German state of Baden-Württemberg, specialises in the development, production and sale of high-quality plastic laboratory products. Greiner Bio-One is part of the Greiner Group, one of the leading companies in the plastics and foam industries, which is celebrating its 150th anniversary this year.

Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilisation. IAs an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors. In 2016, Greiner Bio-One International GmbH generated a turnover of 452 million euros and had over 2,000 employees, 25 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).

Greiner Bio-One BioScience Division
The BioScience division of Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures. Drawing on decades of experience with cryogenic sample storage, Greiner Bio-One also offers solutions for automated storage systems in biobanks. In addition, we continue to utilise our expertise in the development and production of microplates for high-throughput screening, thereby allowing extremely fast and efficient drug screening for both industrial and research applications. The entire development, manufacturing and sales operations are controlled from the German headquarters of the BioScience division in Frickenhausen.

Company-Contact
Greiner Bio-One GmbH
Simone Schafstein & Sylvia Bauer
Maybachstraße 2
72636 Frickenhausen
Phone: 0049-7022-948 0
Fax: 0049-7022-948-514
E-Mail: marketing@de.gbo.com
Url: https://www.gbo.com/en_DE.html

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Business Economy Finances

Expert additions to the team

HR news – two biologists have been providing support for project management at BioRegio STERN Management GmbH since February

Expert additions to the team

Biologists Nina Zabel and Jana Fesseler (from left) provide support for BioRegio STERN (Source: private)

(Stuttgart) – Two more biologists – Jana Fesseler and Nina Zabel – are now providing support for project management at BioRegio STERN Management GmbH. The company, which promotes economic development in the life sciences industry, recently secured numerous new projects, which has resulted in it having to increase its workforce significantly. Among other things, BioRegio STERN Management GmbH has taken on the role of coordinator in the joint APRONA project and is the German lead partner for the Interreg project Codex4SMEs.

A „flexible robot-based platform for automated production of nanoparticles“ is to be developed within the next two and a half years. A transnational network is also being set up to drive forward the development of companion diagnostics along the entire value chain of small and medium-sized enterprises (SME). However, APRONA and Codex4SMEs are just two of the projects that BioRegio STERN Management GmbH has recently procured. „To successfully implement both these and other national and international projects, it was urgently necessary to expand the workforce,“ explains Managing Director Dr. Klaus Eichenberg. „I’m delighted we’ve been able to expand our team so expertly with Jana Fesseler and Nina Zabel. But if things continue to develop in this way, we’ll probably have to allow for even more hires.“

Fesseler and Zabel, both biologists (M.Sc.), started their work in Stuttgart in February 2018.
Jana Fesseler (27) completed a degree in biosciences at the University of Kaiserslautern, which she rounded off with a bachelor thesis on bioprocess engineering and technology. For her subsequent master’s degree in biotechnology, she transferred to the Karlsruhe Institute of Technology (KIT), where she focused on the manufacture of bio-based products from renewable raw materials for the industrial biotechnology sector.
Nina Zabel (27) studied biology at the University of Hohenheim. During a practical semester at Greiner Bio-One GmbH, she gained an insight into the development process for products destined for specific applications in medical, pharmaceutical and biotechnological research and wrote her thesis in Hohenheim at the Institute for Membrane Physiology in collaboration with Greiner Bio-One GmbH. During this, she characterised magnetic nanoparticles and investigated their influence on cellular parameters.

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH promotes economic development in the life sciences industry, helping to strengthen the region as a business location by supporting innovations and start-up companies in the public interest. It is the main point of contact for company founders and entrepreneurs in the Stuttgart and Neckar-Alb regions, including the cities of Tübingen and Reutlingen.
The STERN BioRegion is one of the largest and most successful bioregions in Germany. Its unique selling points include a mix of biotech and medtech companies that is outstanding in Germany and regional clusters in the fields of automation technology and mechanical engineering.

Company-Contact
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
Phone: +49 (0)711-870354-0
E-Mail: info@bioregio-stern.de
Url: http://www.bioregio-stern.de/en

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Strasse 58a
70184 Stuttgart
Phone: +49 (0)711-6070719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Construction of new spinning plant for Planova™ filters

Construction of new spinning plant for Planova™ filters

Planova virus removal filters from Asahi Kasei (Source: @Asahi Kasei)

Düsseldorf, January 16, 2018 – Asahi Kasei Medical will construct a new plant for the spinning of cellulose hollow-fiber membranes for Planova™ virus removal filters in Nobeoka, Miyazaki, Japan, increasing annual production capacity by 40,000 m2/year upon completion in May 2019.

Virus removal filters are used to enhance safety in the production process for biotherapeutic products such as biopharmaceuticals and plasma derivatives. Asahi Kasei Medical has earned wide recognition among customers around the world for the performance and reliability of its virus removal filters-both Planova™ cellulose membrane filters, which were launched in 1989 as the world’s first filters developed specifically for removing viruses from biotherapeutic products, and Planova™ BioEX hydrophilic PVDF (polyvinylidene fluoride) membrane filters, which provide superior viral clearance in high protein concentration solutions.

With heightened standards throughout the world for the viral safety of biotherapeutics and advances in the development of monoclonal antibodies and other biopharmaceuticals, global demand for Planova™ filters is expected to continue on growing. The new spinning plant will enable Asahi Kasei Medical to maintain stable product supply and meet rising demand. Together with a spinning plant for Planova™ BioEX filters completed in Oita, Japan, in 2016, the new spinning plant announced today will increase Asahi Kasei Medical“s total production capacity for hollow-fiber virus removal membranes to 130,000 m2/year.

„This investment to increase production capacity will ensure our sustainable and stable supply to meet all customer“s increasing needs. The mission of Asahi Kasei Medical“s bioprocess business is „Pioneering Biologics Safety and Manufacturing Efficiency“, and with that we want to contribute further to the development and evolution of the bioprocessing industry“, Takeshi Himeno, President of Asahi Kasei Medical says.

Outline of the new spinning plant

Location:Nobeoka, Miyazaki, Japan*
Capacity:40,000 m2/year
Groundbreaking:April 2018
Completion:May 2019

* Adjacent to existing facilities for spinning hollow fiber and assembly of Planova™ filters

About the Asahi Kasei Corporation
The Asahi Kasei Corporation is a globally active technology group that works in the three business areas of Material, Homes and Health Care. Material includes fibres & textiles, petrochemicals, high-performance polymers, high-performance plastics, consumer products, battery separators and electronics. Homes offers construction material to finished houses on the Japanese market. The area Health Care includes pharmaceuticals, medical technology, as well as devices and systems for acute and intensive medicine. With about 34,000 employees across the world, the Asahi Kasei Group supports customers in more than 100 countries.

„Creating for Tomorrow“. With this slogan, the Asahi Kasei Group refers to the common mission of all its companies, to help people across the world towards a better life and living with sustainable products and technologies. You can find further information at

www.asahi-kasei.co.jp/asahi/en/
https://www.asahi-kasei.eu/

The Asahi Kasei Group is a diversified group of companies led by Asahi Kasei Corp., with operations in the Material, Homes, and Health Care business sectors. Asahi Kasei distributes its innovative technologies and unique materials on markets worldwide.
With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world.

Company-Contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-Mail: Sebastian.Schmidt@asahi-kasei.eu
Url: https://www.asahi-kasei.eu/

Press
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Phone: +49 (0) 6172 27159 12
E-Mail: h.kuell@financial-relations.de
Url: http://www.financial-relations.de

Business Economy Finances

Understand industries, connect industries

HR news BioRegio STERN Management GmbH – Biotechnologist Dr. Verena Grimm is new project manager

Understand industries, connect industries

Dr. Verena Grimm, project manager BioRegio STERN Management GmbH (Source: private)

(Stuttgart) – Dr. Verena Grimm joined the BioRegio STERN Management GmbH team as a project manager in January 2017. The biotechnologist completed a tri-national degree course in Germany, Switzerland and France at the Ecole superieure de Biotechnologie de Strasbourg. After undertaking her dissertation at the University of Michigan in the United States, she received a doctorate from the Institute of Technical Biochemistry at the University of Stuttgart. She then worked for Greiner Bio-One GmbH for ten years as a product and marketing manager for multiplex analysis methods used in food safety, pharmaceutical product safety and human diagnostics. „This broad-ranging knowledge enables me to understand and reach various industries more easily,“ explains the 41-year-old. „As a project manager for BioRegio STERN Management GmbH, I will be able to put my expertise in developing, applying and marketing biotechnological methods to good use in improving links between local companies in the medical technology and biotechnology industry and help them develop opportunities for automated applications.“

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and ad-vice centre for founders of new businesses, entrepreneurs and researchers in the life sciences sector in the cities of Stuttgart, Tübingen, Esslingen and Reutlingen and the Stuttgart and Neckar-Alb regions. BioRegio STERN Management GmbH represents the interests of these market players in dealings with political circles, the media and associations and provides advice on grant applications and corporate financing. Key focal points include regenerative medicine, medical technology and the automation of biotechnology. Managing Director Dr. Klaus Eichenberg is a molecular and cell biologist and investment analyst.

Firmenkontakt
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
+49 (0)711-870354-0
info@bioregio-stern.de
http://www.bioregio-stern.de/en

Pressekontakt
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Strasse 58a
70184 Stuttgart
+49 (0)711-6070719
info@zeeb.info
http://www.zeeb-kommunikation.de

Computer IT Software

Scil Proteins aus Halle schneidert Proteine nach Maß

Scil Proteins aus Halle schneidert Proteine nach Maß

(Mynewsdesk) International führender Spezialist für die Optimierung von Proteinen aus Sachsen-Anhalt auf der BIO International Convention in San Fransisco

Das Biotechnologie-Unternehmen Scil Proteins aus der Stadt Halle im deutschen Bundesland Sachsen-Anhalt entwickelt maßgeschneiderte Proteine, die sowohl für die Aufreinigung von Biopharmazeutika als auch für diagnostische Zwecke genutzt werden können. Das Unternehmen agiert international als führender Spezialist für die Optimierung von Proteinen und erwartet, 2018 Profitabilität zu erreichen.

Das kleine Biotechnologie-Unternehmen aus Sachsen-Anhalt, mit 36 Mitarbeitern, sieht sich als Spezialist und europäischer Marktführer im Bereich der Modifikation von Proteinen, dem „Protein Engineering”. Lesen Sie dazu mehr im vollständigen Artikel: http://lsaurl.de/btUr

Vom 6. bis zum 9. Juni präsentiert die IMG den Biotechnologie-Standort Sachsen-Anhalt auf der BIO International Convention 2016 in San Francisco. Auch das Unternehmen Scil Proteins präsentiert sich vor Ort.

Diese Pressemitteilung wurde via Mynewsdesk versendet. Weitere Informationen finden Sie im Investitions- und Marketinggesellschaft Sachsen-Anhalt mbH .

Shortlink zu dieser Pressemitteilung:
http://shortpr.com/bdn0p4

Permanentlink zu dieser Pressemitteilung:
http://www.themenportal.de/multimedia/scil-proteins-aus-halle-schneidert-proteine-nach-mass-81359

Hintergrund zur IMG Sachsen-Anhalt mbH

Die Investitions- und Marketinggesellschaft Sachsen-Anhalt mbH (IMG) ist die Ansiedlungs- und Marketingagentur des deutschen Bundeslandes Sachsen-Anhalt. 

Die Mitarbeiter der IMG bieten alle Leistungen rund um die Ansiedlung im Land von der Akquisition bis zum Produktionsstart. Außerdem vermarktet die IMG den Wirtschafts- und Wissenschaftsstandort nach außen und zeichnet verantwortlich für das Tourismusmarketing im In- und Ausland. 

Das Land Sachsen-Anhalt ist einziger Gesellschafter der IMG. Weiterführende Informationen zu unseren Leistungen finden Sie hier.: http://www.investieren-in-sachsen-anhalt.de/wir-ueber-uns

Firmenkontakt
Investitions- und Marketinggesellschaft Sachsen-Anhalt mbH
Mandy Bunge
Am Alten Theater 6
39104 Magdeburg
+49 391 568 99 73
mandy.bunge@img-sachsen-anhalt.de
http://www.themenportal.de/multimedia/scil-proteins-aus-halle-schneidert-proteine-nach-mass-81359

Pressekontakt
Investitions- und Marketinggesellschaft Sachsen-Anhalt mbH
Mandy Bunge
Am Alten Theater 6
39104 Magdeburg
+49 391 568 99 73
mandy.bunge@img-sachsen-anhalt.de
http://shortpr.com/bdn0p4

Business Economy Finances

Global OEM strategy with a wealth of expertise and experience

Global OEM strategy with a wealth of expertise and experience

Multi-cavity injection mould

Frickenhausen, 15 September 2014 – Greiner Bio-One GmbH, a technology partner for the diagnostic and pharmaceutical industries and the medical sector, is strengthening its position as an OEM developer and producer. In recognition of the company’s growing importance as an original equipment manufacturer, a dedicated global sales organisation for OEM development and production is now being added to its BioScience, Preanalytics and Diagnostics divisions. Appropriately enough, an independent study recently confirmed Greiner Bio-One’s exceptional level of competence in OEM projects.

Greiner Bio-One GmbH (https://www.gbo.com/en_DE.html) develops, produces and distributes plastic laboratory products. It is also a technology partner for hospitals, laboratories, universities, and the diagnostic, pharmaceutical and biotechnology industries. In addition to this core business, Greiner Bio-One is an OEM supplier of customised products for well-known life science and medical companies. To further extend its OEM activities, it is setting up a dedicated global sales organisation.

„We have outstanding expertise in the surface modification of plastics as we have played an active role in plastics processing in the life science and medical sectors for the past 50 years,“ explains Greiner Bio-One’s German Managing Director Heinz Schmid. „This has given us a wealth of experience in development, project planning, production and quality control,“ he adds. A recent study by Nürtingen-Geislingen University confirmed OEM customers‘ high level of satisfaction. The company obtained particularly good ratings in the „Technical development process“, „Manufacturing“ and „Product quality“ categories.

Greiner Bio-One delivers both small and large projects for customers, including everything from simple branding (private labelling) of existing products to specific, custom made solutions as part of a system partnership (true OEM). The product portfolio ranges from basic consumer items to customer-specific medical diagnostic kits. The company also manufactures customised plastic microfluidic product solutions for handling samples and develops individual products for taking samples of bodily fluids such as blood, urine and saliva for preanalytical applications.

Schmid is jointly responsible for OEM activities and is one hundred percent convinced by the company’s strategy. „Our experience and know-how in our core business enables us to stand out from the competition and we also know our customers‘ customers. They use our blood collection tubes and Petri dishes on their equipment and because we know and understand their requirements, we can offer complete solutions that extend from the original idea all the way through to the finished product,“ he says.

Greiner Bio-One GmbH, complete with its new OEM division, will be participating in the CPhl Worldwide pharmaceutical trade fair in Paris, France, from 7 to 9 October 2014.

Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into four divisions – Preanalytics, BioScience, Diagnostics and OEM. In 2013, Greiner Bio-One International GmbH generated a turnover of 373 million euros and had over 1,700 employees, 23 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).

Greiner Bio-One GmbH – BioScience division
With its BioScience division, Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures as well as microplates for high-throughput screening, thereby allowing extremely fast and efficient drug screening in both industry and research applications.

Greiner Bio-One GmbH – Preanalytics division
Greiner Bio-One’s Preanalytics division develops systems for taking samples of blood, urine and saliva based on the requirements of customers and the diagnostics market. These systems simplify day-to-day routine tasks in clinics, laboratories and medical practices and, above all, make them safer.

Greiner Bio-One GmbH – Diagnostics division
This division encompasses four strategic areas in the field of diagnostics – screening procedures for sexually transmitted diseases, hospital pathogens, vaccine safety and customer-specific products. Two fundamentally different detection systems are able to address the requirements of mass analysis (screening), on the one hand, and the needs of individual analyses in acute medicine, on the other.

Firmenkontakt
Greiner Bio-One GmbH
Frau Sylvia Bauer
Maybachstrasse 2
72636 Frickenhausen
0049-7022-948 0
0049-7022-948-514
marketing@de.gbo.com
https://www.gbo.com/en_DE.html

Pressekontakt
Zeeb Kommunikation GmbH
Frau Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
0711-60 70 719
info@zeeb.info
www.zeeb-kommunikation.de

Business Economy Finances

Global OEM strategy with a wealth of expertise and experience

Global OEM strategy with a wealth of expertise and experience

Multi-cavity injection mould

Frickenhausen, 15 September 2014 – Greiner Bio-One GmbH, a technology partner for the diagnostic and pharmaceutical industries and the medical sector, is strengthening its position as an OEM developer and producer. In recognition of the company’s growing importance as an original equipment manufacturer, a dedicated global sales organisation for OEM development and production is now being added to its BioScience, Preanalytics and Diagnostics divisions. Appropriately enough, an independent study recently confirmed Greiner Bio-One’s exceptional level of competence in OEM projects.

Greiner Bio-One GmbH (https://www.gbo.com/en_DE.html) develops, produces and distributes plastic laboratory products. It is also a technology partner for hospitals, laboratories, universities, and the diagnostic, pharmaceutical and biotechnology industries. In addition to this core business, Greiner Bio-One is an OEM supplier of customised products for well-known life science and medical companies. To further extend its OEM activities, it is setting up a dedicated global sales organisation.

„We have outstanding expertise in the surface modification of plastics as we have played an active role in plastics processing in the life science and medical sectors for the past 50 years,“ explains Greiner Bio-One’s German Managing Director Heinz Schmid. „This has given us a wealth of experience in development, project planning, production and quality control,“ he adds. A recent study by Nürtingen-Geislingen University confirmed OEM customers‘ high level of satisfaction. The company obtained particularly good ratings in the „Technical development process“, „Manufacturing“ and „Product quality“ categories.

Greiner Bio-One delivers both small and large projects for customers, including everything from simple branding (private labelling) of existing products to specific, custom made solutions as part of a system partnership (true OEM). The product portfolio ranges from basic consumer items to customer-specific medical diagnostic kits. The company also manufactures customised plastic microfluidic product solutions for handling samples and develops individual products for taking samples of bodily fluids such as blood, urine and saliva for preanalytical applications.

Schmid is jointly responsible for OEM activities and is one hundred percent convinced by the company’s strategy. „Our experience and know-how in our core business enables us to stand out from the competition and we also know our customers‘ customers. They use our blood collection tubes and Petri dishes on their equipment and because we know and understand their requirements, we can offer complete solutions that extend from the original idea all the way through to the finished product,“ he says.

Greiner Bio-One GmbH, complete with its new OEM division, will be participating in the CPhl Worldwide pharmaceutical trade fair in Paris, France, from 7 to 9 October 2014.

Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into four divisions – Preanalytics, BioScience, Diagnostics and OEM. In 2013, Greiner Bio-One International GmbH generated a turnover of 373 million euros and had over 1,700 employees, 23 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).

Greiner Bio-One GmbH – BioScience division
With its BioScience division, Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures as well as microplates for high-throughput screening, thereby allowing extremely fast and efficient drug screening in both industry and research applications.

Greiner Bio-One GmbH – Preanalytics division
Greiner Bio-One’s Preanalytics division develops systems for taking samples of blood, urine and saliva based on the requirements of customers and the diagnostics market. These systems simplify day-to-day routine tasks in clinics, laboratories and medical practices and, above all, make them safer.

Greiner Bio-One GmbH – Diagnostics division
This division encompasses four strategic areas in the field of diagnostics – screening procedures for sexually transmitted diseases, hospital pathogens, vaccine safety and customer-specific products. Two fundamentally different detection systems are able to address the requirements of mass analysis (screening), on the one hand, and the needs of individual analyses in acute medicine, on the other.

Firmenkontakt
Greiner Bio-One GmbH
Frau Sylvia Bauer
Maybachstrasse 2
72636 Frickenhausen
0049-7022-948 0
0049-7022-948-514
marketing@de.gbo.com
https://www.gbo.com/en_DE.html

Pressekontakt
Zeeb Kommunikation GmbH
Frau Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
0711-60 70 719
info@zeeb.info
www.zeeb-kommunikation.de

Science Research Technology

Yeast-Based Bioplastics and Pharmaceuticals

Yeast-Based Bioplastics and Pharmaceuticals

Prof. Dr. Christine Lang, CEO of Organobalance

White Biotech to Reduce Pressure on Resources and Environment

Employing microbiological processes to utilize plant materials – often referred to as industrial or „white biotechnology“ – helps optimize our use of limited natural resources and preserves Nature and the environment. This was emphasized by Prof. Dr. Christine Lang, chair of the Federal Government’s Bioeconomy Council, in a presentation at the Ecochem Conference in Basle. The objective of biotechnology and bioeconomy must be to use natural plant materials wisely and judiciously in the production of new profitable substances, she said.

One example was succinic acid (spirit of amber), used as a precursor in plastics, which could be produced from renewable resources with the help of baker’s yeast. Currently, production remains generally petroleum-based, using high-temperature synthesis with correspondingly high power consumption and involving solvents with harmful environmental effects.

Christine Lang is the CEO of the Berlin-based biotechnology company Organobalance . The company has a collection of more than 8,000 strains of yeast and lactic acid bacteria which has already provided natural agents against bacterial infections, e.g. caries. „Nature offers so many means which we can utilize in the industrial production of everyday products or to treat or prevent diseases“, says Prof. Lang. „This is why we want and have to continue our research into these positive characteristics of microorganisms.“

Another example mentioned by Ms. Lang was squalene, a compound used in pharmaceuticals and cosmetics and obtained from shark liver. „Here, too, systematic screening of yeast and lactic acid bacteria will enable us to find alternatives which reduce the pressure on the environment and animal populations“, the scientist stressed.

Ecochem is a sustainable chemistry and engineering conference and trade event. The inaugural edition took place from 19-21 November 2013 in Basle, Switzerland.

Christine Lang (born 1957) majored in biology at the Ruhr-University Bochum and at the University of Sussex. After completing her Ph D., she worked in industrial research before moving on to the Technische Universität Berlin where she became professor of microbiology and molecular genetics. In 2001, she set up the biotechnology company Organobalance. Ms. Lang is actively involved in several trade and professional associations in the biotechnology sector. Furthermore, she is co-chair of the Federal Government“s Bioeconomy Council. She has won several prizes for her entrepreneurial and scientific work.

Kontakt
ORGANOBALANCE GmbH
Prof. Dr. Christine Lang
Gustav-Meyer-Allee 25
13355 Berlin
+49 (0)30 46307 200
info@organobalance.com
http://www.organobalance.de

Pressekontakt:
ORGANOBALANCE GmbH / Claudius Kroker · Text & Medien
Dr. Klaus Pellengahr
Gustav-Meyer-Allee 25
13355 Berlin
+49 (0)30 46307 200
organobalance@ck-bonn.de
http://www.organobalance.de

Wirtschaft Handel Maschinenbau

CashReport: Die erste Schweizer Biotec – Messe findet im Jahre 2014 statt.

„Swiss- Biotec- Forum“ soll in den nächsten Jahren zur Leitmesse in Europa aufgebaut werden.

CashReport: Die erste Schweizer Biotec - Messe findet im Jahre 2014 statt.

Im kleinen liegt der Anfang.

Zur Veranstaltung „Swiss- Biotec- Forum“

Die Schweiz zählt zu den wichtigsten Ländern im Segment Biotec, es werden jährlich bis zu 11 Milliarden Schweizer Franken umgesetzt, die Branche beschäftigt alleine in der Schweiz derzeit 21’000 Personen, mit einer jährlichen Zuwachsrate von 4 bis 5%. Im internationalen Ranking belegt die Schweiz im Bereich Biotec immer die ersten drei Plätze, wenn es um Neuentwicklungen von Produkten und Anwendungen geht.

Die Schweiz spielt folglich eine zentrale Rolle in der weltweiten Biotec- Industrie und profitiert volkswirtschaftlich von dem Industriezweig.

Aus diesem Grunde, organisiert CashReport im Jahre 2014, die erste nationale & internationale Biotec- Messe in der Schweiz. Die Veranstaltung soll im jährlichen Tourenplan in Bern stattfinden.

Das „Swiss-Biotec-Forum“ steht für Techologie, Schaffung von Werthaltig und Nachhaltig und soll sich in den nächsten Jahren als Leitmesse für Biotechologie und Life Sciences in Europa entwickeln. Ziel soll es sein, die gesamte Wertschöpfungskette der Biotec- Branche auf der Plattform zu vereinen.

Gleichzeitig wird parallel zur Messe ein Fachforum mit verschieden Thematiken auf- und ausgebaut.

Was steht im Fokus der Veranstaltung?

✔ Neuste Technologien: Von Forschung und Entwicklung
über die Produkt- und Stoffumwandlung bis zur
Aufarbeitung erwarten Sie neue Ideen, Produkte und
Anwendungsbeispiele.
✔ Bioverfahrenstechnik: Neben klassischen Ausrüstern,
die Konzepte, Geräte und Anlagen für die biotechnologische
Produktion vom Labor- bis zum Industriemaßstab
präsentieren, umfasst dieser Ausstellungsschwerpunkt
außerdem die Entwicklung und
Optimierung maßgeschneiderter Bioprozesse.
✔ Bioanalytik: Entdecken Sie innovative Sensortechnik
und Analysegeräte.
✔ Bioinformatik: Dieser Bereich zeigt Lösungen in Hinblick
auf Planung und Steuerung von biotechnologischen
Prozessen sowie zur Auslegung von Experimenten.
✔ Biotech-Dienstleister: Präsentationen entlang der
gesamten Wertschöpfungskette – von Auftragsforschung,
-produktion und -analytik bis hin zu Wirtschaftsförderern
und Technologieparks erwarten Sie.
Biotechnologische

Die Swiss- Biotec Marktplätze:

Personalized Medicine Technologies

Hier dreht sich alles um molekulare Diagnostik und die
damit zusammenhängenden individualisierten Therapieansätze.
Im Forum werden Fragen beantwortet, was Key
Player unter personalisierter Medizin verstehen und welche
Technologien dafür benötigt werden.

Industrial Biotechnology

Biotechnologische Verfahren halten verstärkt Einzug in
industrielle Fertigungsprozesse und schaffen das Fundament
für neue Produktentwicklungen.

BioServices

Komplexe biotechnologische Entwicklungsprojekte von
Biopharmazeutika erfordern eine zielführende Zusammenarbeit
spezialisierter Dienstleister entlang der gesamten
Wertschöpfungskette.

Innovation

Akteure aus der Biotec Branche präsentieren
neue Möglichkeiten und Konzepte.

Veranstaltungsort/ -termin:

Das erste Swiss-Biotec- Forum findet im Herzen von Bern statt, das genaue Datum wird noch bekannt gegeben.

Kontakt:
OCI Ltd
James Balmer
95 Wilton Road, 
Suite 3 

SW1V 1BZ London
41 22 575 49 10
info@cash-report.ch
www.cash-report.eu

Kunst Kultur Gastronomie

Biotechnologie – Exklusiv-Umfrage 2012/2013

Best-Practice-Einkauf in einer Zukunftsbranche

Biotechnologie - Exklusiv-Umfrage 2012/2013

(NL/9710791177) Biotechnologie eröffnet neue Wege und gilt weiterhin als wirtschaftlicher Innovationsmotor für die Zukunft.Leider ist die Branche nach verschiedenen Hypes aktuell aus dem Fokus des Interesses gerückt und findet kaum Beachtung. Die Exklusiv-Umfrage beleuchtet die Performance der Einkaufsabteilung einer nach Experten-Meinungen immer noch potentialträchtigen Zukunftsbranche.

Biotechnologie – Exklusiv-Umfrage 2012/2013: Best-Practice-Einkauf in einer Zukunftsbranche

Biotechnologie eröffnet neue Wege und gilt weiterhin als wirtschaftlicher Innovationsmotor für die Zukunft.Leider ist die Branche nach verschiedenen Hypes aktuell aus dem Fokus des Interesses gerückt und findet kaum Beachtung.

Die vorliegende Exklusiv-Umfrage soll in den Bereichen Einkauf und Supply Chain Management ein neues Bewusstsein für Experten schaffen, denn in kaum einer anderen Branche steht der Beschaffungsbereich auf der einen Seite so unter Kosten- und Qualitätsdruck und liefert auf der anderen Seite dementsprechend innovative Lösungsansätze wie in der Biotechnologie. Die Exklusiv-Umfrage beleuchtet die Performance der Einkaufsabteilung einer nach Experten-Meinungen immer noch potentialträchtigen Zukunftsbranche. Neben Potenzialen, Strategien und Trends im Einkauf und dem Supply Chain Management werden auch Themen wie z. B. Standing der Abteilung im Unternehmen, Einkaufsstrategie, strategisches Lieferantenmanagement, Risikomanagement, Global Sourcing und Weiterbildung für Einkäufer untersucht. Darüber hinaus wird aufgezeigt, wie sich die Einkaufs-und Supply Chain Champions der Branche vom Durchschnitt unterscheiden.

Das Erfolgsrezept der Einkaufs- und SCM-Champions
Die Ergebnisse der Exklusiv-Umfrage werden als Benchmark zur Verfügung gestellt und können auf diese Weise genutzt werden, um Optimierungspotentiale abzuleiten. Gleichzeitig soll mit dieser Veröffentlichung die Biotechnologie-Branche unterstützend wieder mehr in den Fokus des öffentlichen (Einkaufs-)Interesses gerückt werden.

Das Ergebnispapier ist für 195,00 Euro zzgl. MwSt. erhältlich bei Deutsche Business Consulting GmbH, www.deutsche-bc.com.

Name: Biotechnologie -Exklusiv-Umfrage 2012/2013
Sprache: Deutsch
Erscheinungsjahr: 2012/2013
Wörter:210
Zeichen inkl. Leerzeichen: 1.736

Kontakt:
Deutsche Business Consulting GmbH
Gabriel Kruppa
Du-Pont-Str. 6
61352 Bad Homburg
49 6172 85010-57
gabriel.kruppa@deutsche-bc.com
www.deutsche-bc.com